Munich-based biotech startup IRUBIS, which is developing a state-of-the-art real-time solution for bioprocess monitoring, has successfully closed a Pre-Series A financing round. The financing round was led by BioProcess360 Partners, with participation from existing investors such as High-Tech Gründerfonds (HTGF), Verve Ventures, Ventura BioMed Investors, RoBet KG as well as new and existing business angels from the industry such as Dr. Matthias Arnold and Dr. Christoph Bremus.
IRUBIS will use the funds to further develop its innovative solution Monipa, which is tailored to make bioprocesses more efficient and precise. IRUBIS' innovative process analytical technology (PAT), Monipa, is based on mid-infrared spectroscopy. It serves as a user-friendly and powerful tool for the prediction of critical quality attributes (CQAs) and critical process parameters (CPPs) in upstream and downstream bioprocesses.
The use of inline and online measurement methods aims at higher yield and better quality and enables the automation of the production of many life-saving drugs. This innovative approach gives Monipa a major advantage over conventional techniques and is the answer to many challenges in the bioprocess industry.
IRUBIS was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler and Anja Müller with the aim of bringing life-saving biopharmaceutical drugs to patients faster. Lead investor BioProcess360 of the Pre-Series A financing wants to actively and practically support the company in developing and implementing a successful growth strategy to achieve its goals.